^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
polzastobart (JTX-8064)
i
Other names: JTX-8064
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Concentra Biosci
Drug class:
HLA G inhibitor, ILT-4 inhibitor
Related drugs:
10ms
INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1/2, N=190, Completed, Jounce Therapeutics, Inc. | Active, not recruiting --> Completed | N=281 --> 190
Trial completion • Enrollment change • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
|
EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation
|
pimivalimab (JTX-4014) • polzastobart (JTX-8064)
over1year
INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1/2, N=281, Active, not recruiting, Jounce Therapeutics, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
|
EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation
|
pimivalimab (JTX-4014) • polzastobart (JTX-8064)
over1year
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors. (PubMed, Mol Cancer Ther)
In a human tumor explant culture, pharmacodynamic activity of JTX-8064 was observed in monotherapy and in combination with anti-PD-1. Collectively, our work provides strong translational and pre-clinical rationale to target LILRB2 in cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD163 (CD163 Molecule) • ITGAM (Integrin, alpha M)
|
CD163 expression
|
polzastobart (JTX-8064)
almost3years
INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1/2, N=281, Recruiting, Jounce Therapeutics, Inc. | Phase classification: P1 --> P1/2
Phase classification • Combination therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
pimivalimab (JTX-4014) • polzastobart (JTX-8064)
over3years
INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=281, Recruiting, Jounce Therapeutics, Inc. | N=40 --> 281 | Trial completion date: Sep 2022 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Sep 2023
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
pimivalimab (JTX-4014) • polzastobart (JTX-8064)
Share via
